LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

Search

Incyte Corp

Slēgts

SektorsVeselības aprūpe

85.63 -1.03

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

85.27

Max

86.55

Galvenie mērījumi

By Trading Economics

Ienākumi

247M

405M

Pārdošana

163M

1.2B

P/E

Sektora vidējais

20.002

35.733

EPS

1.16

Peļņas marža

33.319

Darbinieki

2,617

EBITDA

324M

582M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

-2.96% downside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 28. okt.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

2.9B

17B

Iepriekšējā atvēršanas cena

86.66

Iepriekšējā slēgšanas cena

85.63

Ziņu noskaņojums

By Acuity

67%

33%

332 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 9. sept. 23:37 UTC

Karstas akcijas

Stocks to Watch: Oracle, Wearable Devices, GameStop

2025. g. 9. sept. 20:41 UTC

Peļņas

Oracle's Backlog Surges With Major Customer Deals in 1Q

2025. g. 9. sept. 20:30 UTC

Peļņas

GameStop 2Q Sales, Profit Rise

2025. g. 9. sept. 23:19 UTC

Tirgus saruna

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

2025. g. 9. sept. 21:35 UTC

Peļņas

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

2025. g. 9. sept. 21:32 UTC

Peļņas

Oracle's Backlog Swells With Big Customer Deals -- Update

2025. g. 9. sept. 21:02 UTC

Iegādes, apvienošanās, pārņemšana

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

2025. g. 9. sept. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 9. sept. 20:33 UTC

Peļņas

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

2025. g. 9. sept. 20:26 UTC

Peļņas

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

2025. g. 9. sept. 20:23 UTC

Peļņas

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

2025. g. 9. sept. 20:12 UTC

Peļņas

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

2025. g. 9. sept. 20:10 UTC

Peļņas

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

2025. g. 9. sept. 20:10 UTC

Peļņas

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

2025. g. 9. sept. 20:09 UTC

Peļņas

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

2025. g. 9. sept. 20:09 UTC

Peļņas

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

2025. g. 9. sept. 20:08 UTC

Peļņas

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

2025. g. 9. sept. 20:08 UTC

Peļņas

Oracle 1Q Operating Income Was $4.3 B >ORCL

2025. g. 9. sept. 20:08 UTC

Peļņas

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

2025. g. 9. sept. 20:08 UTC

Peļņas

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

2025. g. 9. sept. 20:07 UTC

Peļņas

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

2025. g. 9. sept. 20:06 UTC

Peļņas

Oracle 1Q Software Revenue $5.72B >ORCL

2025. g. 9. sept. 20:06 UTC

Peļņas

Synopsys 3Q Adj EPS $3.39 >SNPS

2025. g. 9. sept. 20:06 UTC

Peļņas

Oracle 1Q Cloud Revenue $7.19B >ORCL

2025. g. 9. sept. 20:05 UTC

Peļņas

Oracle 1Q Rev $14.93B >ORCL

2025. g. 9. sept. 20:05 UTC

Peļņas

Oracle 1Q EPS $1.01 >ORCL

2025. g. 9. sept. 20:05 UTC

Peļņas

Synopsys 3Q EPS $1.50 >SNPS

2025. g. 9. sept. 20:05 UTC

Peļņas

Oracle 1Q Services Revenue $1.35B >ORCL

2025. g. 9. sept. 20:05 UTC

Peļņas

Oracle 1Q Adj EPS $1.47 >ORCL

2025. g. 9. sept. 20:05 UTC

Peļņas

Oracle 1Q Hardware Revenue $670M >ORCL

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

-2.96% uz leju

Prognoze 12 mēnešiem

Vidējais 84 USD  -2.96%

Augstākais 110 USD

Zemākais 60 USD

Pamatojoties uz 19 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

19 ratings

10

Pirkt

8

Turēt

1

Pārdot

Tehniskais rādītājs

By Trading Central

59.52 / 62.66Atbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

332 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
help-icon Live chat